Share Twitter LinkedIn Facebook Email Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read
New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 4 Mins Read